MCM
AERI

Moore Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Moore Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-40,000
Closed -$1.51M – 303
2016
Q3 		$1.51M Buy
+40,000
New +$882K 0.05% 143

Other funds holding AERI

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's AERI Position: Q4 2016 in Review

Moore Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2016, closing a stake of 40,000 shares — an estimated $1.51M sold.

Moore Capital Management first reported a position in AERI in Q3 2016 and held it in 1 quarter. The position peaked at $1.51M in Q3 2016. 151 funds tracked by Wall St. Rank hold AERI as of Q4 2016.

  • Moore Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Moore Capital Management sold 40,000 Aerie Pharmaceuticals shares in Q4 2016, an estimated $1.51M.
  • Moore Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Moore Capital Management's Aerie Pharmaceuticals position peaked at $1.51M in Q3 2016.
  • 151 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2016.

Based on Moore Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.